Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

02/05/19

BERKELEY HEIGHTS, N.J. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2019
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019

01/07/19

BERKELEY HEIGHTS, N.J. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2018
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

12/27/18

BERKELEY HEIGHTS, N.J. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

11/12/18

Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology,
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

11/06/18

BERKELEY HEIGHTS, N.J. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Monday,
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

10/23/18

BERKELEY HEIGHTS, N.J. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the 4 th Annual
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

10/04/18

Multi-product agreement builds on long-term clinical collaboration in hematological malignancies BERKELEY HEIGHTS, N.J. and HOUSTON , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

09/26/18

BERKELEY HEIGHTS, N.J. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announces that the Company will present at the Ladenburg
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

09/12/18

- Former CMO of Schering-Plough Joins Cyclacel Board - BERKELEY HEIGHTS, N.J. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

09/10/18

BERKELEY HEIGHTS, N.J. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase 1b/2 investigator-sponsored

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference

08/29/18

BERKELEY HEIGHTS, N.J. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announces that the Company will present at the 20th Annual H.C.

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results

08/09/18

Conference Call Scheduled August 9, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results

08/01/18

BERKELEY HEIGHTS, N.J. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results

05/14/18

Conference Call Scheduled May 14, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , May 14, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results

05/08/18

BERKELEY HEIGHTS, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other

Read more

PDF Version
Summary Toggle Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

04/17/18

Suppression of both BCl-2 and Mcl-1 anti-apoptotic proteins is a novel strategy in CLL BERKELEY HEIGHTS, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that

Read more

PDF Version
Summary Toggle Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

04/16/18

Durable Mcl-1 suppression of at least 24 hours after a single dose of CYC065 BERKELEY HEIGHTS, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

03/28/18

Conference Call Scheduled March 28, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , March 28, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

03/21/18

BERKELEY HEIGHTS, N.J. , March 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

PDF Version
Summary Toggle Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

03/15/18

Further abstract selected with preclinical data of CYC065 and venetoclax combination in CLL BERKELEY HEIGHTS, N.J. , March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies
Read more

PDF Version

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter